Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

• Type of Material: Article
• Authors: Faith E Davies, NYU Langone Health; Charlotte Pawlyn, The Institute of Cancer Research, London; Saad Z Usmani, Memorial Sloan-Kettering Cancer Center; Jesus F San-Miguel, Universidad de Navarra; Hermann Einsele, Universitätsklinikum Würzburg; Eileen M Boyle, NYU Langone Health; Jill Corre, Inserm; Daniel Auclair, Multiple Myeloma Research Foundation; Hearn Jay Cho, Multiple Myeloma Research Foundation; Sagar Lonial, Emory University; Pieter Sonneveld, Erasmus MC Cancer Institute; Keith A Stewart, Ontario Cancer Institute University of Toronto; Leif A Bergsagel, Mayo Clinic Scottsdale-Phoenix, Arizona; Martin F Kaiser, The Royal Marsden Hospital; Katja Weisel, Universitätsklinikum Hamburg-Eppendorf; Jonathan J Keats, Translational Genomics Research Institute; Joseph R Mikhael, Translational Genomics Research Institute; Kathryn E Morgan, Myeloma Patients Europe; Irend M Ghobrial, Harvard Medical School; Robert Z Orlowski, University of Texas MD Anderson Cancer Center; Ola C Landgren, Sylvester Comprehensive Cancer Center; Francesca Gay, Università degli Studi di Torino; Joseph Caers, Centre Hospitalier Universitaire de Liege; Wee Joo Chng, Indiana University-Purdue University Indianapolis; Ajai Chari, Icahn School of Medicine at Mount Sinai; Brian A Walker, Indiana University-Purdue University Indianapolis; Shaji K Kumar, Mayo Clinic; Luciano J Costa, The University of Alabama at Birmingham; Kenneth C Anderson, Harvard Medical School; Gareth J Morgan, NYU Langone Health
• Language: English
• Date: 2022-07-06
• Publisher: American Association for Cancer Research
• Publication Version: Final Published Version
• Copyright Statement: ©2022 The Authors; Published by the American Association for Cancer Research
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1158/2643-3230.BCD-21-0205
• Title of Journal or Parent Work: Blood cancer discovery
• Volume: 3
• Issue: 4
• Start Page: 273
• End Page: 284
• Keywords: Prognosis; Humans; Multiple Myeloma
• Research Categories: Health Sciences, Oncology

Abstract

The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.